AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC) Meeting Abstract
| Authors: | Rathkopf, D. E.; Chi, K. N.; Olmos, D.; Cheng, H. H.; Agarwal, N.; Graff, J. N.; Sandhu, S. K.; Hayreh, V.; Lopez-Gitlitz, A.; Francis, P. S.; Attard, G. |
| Abstract Title: | AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC) |
| Meeting Title: | 2021 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2021 Feb 11-13 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-02-20 |
| Language: | English |
| ACCESSION: | WOS:000636801500007 |
| DOI: | 10.1200/JCO.2021.39.6_suppl.TPS176 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS176 -- Source: Wos |
